The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors-Reference-Cited by-同舟云学术

The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors

Published:2023-02-24 Issue:7 Volume:72 Page:2127-2135
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Perrone Fabiana,Favari Elda,Maglietta Giuseppe,Verzè Michela,Pluchino Monica,Minari Roberta,Sabato Roberto,Mazzaschi Giulia,Ronca Annalisa,Rossi Alessandra,Cortellini Alessio,Pecci Federica,Cantini Luca,Bersanelli Melissa,Quaini Federico,Tiseo Marcello,Buti Sebastiano

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://link.springer.com/content/pdf/10.1007/s00262-023-03398-3.pdf

Reference27 articles.

1. Quhal F, Mori K, Bruchbacher A, Resch I, Mostafaei H, Pradere B, Schuettfort VM, Laukhtina E, Egawa S, Fajkovic H, Remzi M, Shariat SF, Schmidinger M (2021) First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Oncol 4:755–765. https://doi.org/10.1016/j.euo.2021.03.001

2. Grant MJ, Herbst RS, Goldberg SB (2021) Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol 18:625–644. https://doi.org/10.1038/s41571-021-00520-1

3. Vafaizadeh V, Barekati Z (2020) Immuno-oncology biomarkers for personalized immunotherapy in breast cancer. Front Cell Dev Biol 8:162. https://doi.org/10.3389/fcell.2020.00162

4. Perrone F, Minari R, Bersanelli M, Bordi P, Tiseo M, Favari E, Sabato R, Buti S (2020) The prognostic role of high blood cholesterol in advanced cancer patients treated with immune checkpoint inhibitors. J Immunother 43:196–203. https://doi.org/10.1097/CJI.0000000000000321

5. Tong J 3rd, Mao Y, Yang Z, Xu Q, Zheng Z, Zhang H, Wang J, Zhang S, Rong W, Zheng L 3rd (2021) Baseline serum cholesterol levels predict the response of patients with advanced non-small cell lung cancer to immune checkpoint inhibitor-based treatment. Cancer Manag Res 13:4041–4053. https://doi.org/10.2147/CMAR.S304022

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Levels of serum lipids predict responses to PD-L1 inhibitors as first-line treatment in small cell lung cancer: an observational study;International Journal of Clinical Pharmacy;2024-09-12

2. Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy;Immunotherapy;2024-08-06

3. Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors;Journal of Immunotherapy;2024-07-11

4. Levels of serum lipids predict responses to PD-L1 inhibitor as first-line treatment in small cell lung cancer: an observational study;2024-04-30

5. A combined nomogram based on radiomics and hematology to predict the pathological complete response of neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma;BMC Cancer;2024-04-12